CBP-174 is under clinical development by Suzhou Connect Biopharmaceuticals and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase I drugs for Atopic Dermatitis (Atopic Eczema) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CBP-174’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CBP-174 overview

CBP-174 is under development for the treatment of pruritis in atopic dermatitis and pruritus associated with atopic dermatitis. It is administered orally. It is a small molecule which targets histamine H3 receptor. It was also under development for allergic rhinitis (nasal congestion due to allergy).

Suzhou Connect Biopharmaceuticals overview

Suzhou Connect Biopharmaceuticals (Connect Biopharmaceuticals) discovers and develops next-generation immune modulators for the treatment of autoimmune diseases and inflammation. The company’s pipeline Product portfolio includes CBP-307 is an orally-active small molecule used for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD); CBP-201 is an antibody for asthma and atopic dermatitis; and CBP-174 is a small molecule inhibitor for the treatment of chronic skin inflammation. It utilizes T cell modulation technology platform for developing their products. Connect Biopharmaceuticals serves in the therapeutic areas of inflammatory bowel disease, psoriasis, multiple sclerosis and other autoimmune diseases. The company seeks to collaborate with pharmaceutical companies to develop and commercialize their products both inside and outside China. Connect Biopharmaceuticals is headquartered in Taicang, Jiangsu, China.

For a complete picture of CBP-174’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.